ClinicalTrials.gg
Not yet recruitingNCT06856928Updated Mar 4, 2025

Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.

An observational study in Obesity; Drug, sponsored by University of Colorado, Denver. Not yet recruiting. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by University of Colorado, Denver · Observational

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
16
Ages
25 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Obesity by University of Colorado, Denver — 19 open to participants now, 32 under way, 2 of them phase 3. Obesity · University of Colorado, Denver.

Planned enrollment
17th of 17
16 · median 54
Started
2025
with 5 others
Observational
17 of 105
4 open now
Primary completion
2026-12
later than 10 of 31 live
Registered
100th of 105
by date

Among the 105 studies in Obesity by University of Colorado, Denver, this one is the 17th largest by planned enrollment of the 17 observational ones that give a count, is one of 6 that started in 2025, is one of 17 observational ones, reaches primary completion later than 10 of the 31 other live ones, and was the 100th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

19 of the 105 studies in Obesity by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 25 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Obesity by University of Colorado, Denver, or all of them as a file.
02

Study summary

This study aims to explore how anti-obesity medications (AOMs) like semaglutide and tirzepatide affect appetite and energy intake. Researchers will examine two groups: one just starting AOMs and another that has already achieved significant weight loss and maintained it. By conducting meal challenges at different stages of medication use, the study will assess feasibility of the methods and gather preliminary data to design a larger, future study.

03

Conditions studied

  • Obesity; Drug

Browse trials for

Keywords

  • appetite-related hormones
  • appetite
  • metabolites
04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Potential participants are residents of the Denver metropolitan area who have either:

  1. Had or has obesity and experienced significant weight loss while taking semaglutide or tirzepatide, or
  2. Has obesity and has established agreements with their healthcare providers to begin treatment with semaglutide or tirzepatide.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males and females with a of 30-45 kg/m2 (early group), or a BMI of 30-45 kg/m2 prior to weight loss achieved through medication (late group)
  • Age, 25-60 years old
  • Passing medical and physical screening, and analysis of blood and urine screening samples
  • Anticipated to start or are already prescribed AOMs (semaglutide or tirzepatide)
  • 6-months weight stable (early group) or 3 months weight stable at current weight (late group)
  • Women of reproductive age must be using an effective form of

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with type 1 or 2 diabetes
  • Smoker
  • Previous surgical treatment or device-based therapy for obesity
  • Chronic or acute pancreatitis
  • gastric emptying abnormality
  • Uncontrolled hypertension or hypo/hyperthyroidism
  • Cardiovascular event 3 months within screening
  • Acute or chronic hepatitis
  • Inability to tolerate beef, eggs, and cheese
  • Women who are pregnant
  • Women who are nursing
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
16 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Early Group

    Participants in the early group are individuals that have established agreements with their clinical providers to begin treatment with semaglutide or tirzepatide as part of their ongoing weight management strategy. These participants will complete a meal challenge before they start the medication and 6 weeks after starting medication.

    Other: Meal Challenge

  • Late Group

    Participants in the late group are individuals that have lost \>12% of their body weight on either semaglutide or tirzepatide and are still taking the medication. These participants will complete a meal challenge before they discontinue medication and 3 weeks after discontinuing the medication.

    Other: Meal Challenge

Interventions

  • OtherMeal Challenge

    The meal challenge scheduled for 4-6 days after the patient's last injection. The study team will insert an indwelling venous catheter into the participant's forearm for serial blood draws. Immediately prior to the meal, participants will consume 1500 mg of acetaminophen (off-label) to facilitate the analysis of gastric emptying. The participant will then begin the meal challenge by eating the test meal, a breakfast casserole, containing 33% of their current resting energy expenditure needs estimated by Mifflin-ST Jeor equation with a composition of 50% carbohydrate, 30% fat and 20% protein. Participants must completely consume the test meal within 25 minutes of initiating the meal. Participants will fill out behavioral questionnaires after consuming the test meal. After the 2-hour blood draw period, participants will be dismissed. Blood will be drawn prior to the meal and at 5, 10, 15, 30, 60, 90, and 120 minutes after initiating the meal.

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Participant Recruitment

    Number of participants recruited for the study.

    Time frame: 6-10 weeks

  2. Meal test tolerability

    Number or participants able to tolerate and complete the test meal.

    Time frame: 6-10 weeks

  3. Rate of protocol completion

    Percentage of participants enrolled that complete the protocol

    Time frame: 6-10 weeks

Secondary outcomes

  1. Change in peptide YY (pg/ml)

    Time frame: 6-10 weeks

  2. Change in Glucagon Like Peptide-1 (pg/mL)

    Time frame: 6-10 weeks

  3. Change in leptin (ng/mL)

    Time frame: 6-10 weeks

  4. Change in insulin (uIU/mL)

    Time frame: 6-10 weeks

  5. Change in Glucagon (pg/mL)

    Time frame: 6-10 weeks

  6. Glucose-Dependent Insulinotropic Peptide (pg/mL)

    Time frame: 6-10 weeks

  7. Change in Glucose (mg/dL)

    Time frame: 6-10 weeks

  8. Change in triglycerides (mg/dL)

    Time frame: 6-10 weeks

  9. Change in free fatty acids (uEq/L)

    Time frame: 6-10 weeks

  10. Change in Total Cholesterol (mg/dL)

    Time frame: 6-10 weeks

  11. Gastric emptying by acetaminophen

    Peak acetaminophen concentration in blood

    Time frame: 6-10 weeks

  12. Eating Rate

    Calories/minutes

    Time frame: 6-10 weeks

  13. Changes in subjective hunger by visual analog scale (VAS)

    Line from 0: not hungry to 10: extremely hungry

    Time frame: 6-10 weeks

  14. Changes in subjective fullness by visual analog scale (VAS)

    Line from 0: not full to 10: extremely full

    Time frame: 6-10 weeks

  15. Changes in perceived prospective food consumption by visual analog scale (VAS)

    Line from 0: no desire to eat more to 10: I could eat a large amount.

    Time frame: 6-10 weeks

  16. Changes in subjective nausea by visual analog scale (VAS)

    Line from 0: no nausea at all more to 10: worst nausea possible.

    Time frame: 6-10 weeks

  17. Disinhibition measured by TFEQ

    Disinhibition

    Time frame: 6-10 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Dec 2026, 21 months later.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 21 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Mar 4, 2025
StartEst.
Mar 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06856928
Responsible party
Mark Ezpeleta (Post Doctoral Fellow, University of Colorado, Denver) — Principal investigator
First posted
Mar 4, 2025
Start date
Mar 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion